Privacy Preference Center

Your Privacy

Information may be obtained or stored in your browser by cookies when you access the Website. This information is related to the user, the user settings or device. It is primarily used to ensure the site functions as expected by the user. We respect your right to privacy. Therefore, you can select to not allow some types of cookie. Please click on the different category headings to check the details and then change our default settings.

More Information

Strictly Necessary Cookies

Strictly Necessary Cookies are cookies that are essential for this site to function properly. Strictly Necessary Cookies do not store information that can identify individuals. Strictly Necessary Cookies are used to view this site. Therefore, you cannot refuse the use of Strictly Necessary Cookies from these cookie settings. However, you can refuse the use of Strictly Necessary Cookies from the settings of your browser at any time. Please note that parts of the site may not function if you refuse the use of Strictly Necessary Cookies.

This site uses the following Strictly Necessary Cookies.

Cookie name: gdprCookieEn

  • Purpose:To control the display for the confirmation of cookies on this site
  • Term of validity:1 year

Cookie name: optGA

  • Purpose:To opt out/opt in of (disable/enable) Google Analytics
  • Term of validity:1 year

Cookie name: optPardot

  • Purpose:To opt out/opt in of (disable/enable) Pardot
  • Term of validity:1 year

Google Analytics

You can refuse cookies other than the Strictly Necessary Cookies from the following settings. If you refuse the use of these cookies, we will not know even if you visit this site.

Cookies used

_ga,_ga_{container-id},_gid,_gcl_au

  • Purpose:To statistically research and analyze the usage situation of this Website
  • Term of validity:1 year

Pardot

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site.

All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

Pardot Cookies used

pi_<accountid>,visitor_id<accountid>,visitor_id<accountid>-hash
Ipv<accountid>, pardot

  • Purpose:To provide useful information on products and services
  • Term of validity:1 year

What's New

News

Nippon Kayaku's news releases are issued to inform our stakeholders of the latest information regarding the Company.
While some news releases may contain information about pharmaceutical products (including those under development), they are intended solely for disclosure purposes to members of the media, shareholders, and investors, and are not intended for advertising or promotional purposes, nor to provide medical advice.

2025/11/28
Notice Regarding Fire Extinguishment at Asa Plant (Kawahigashi）
2025/11/28
Notice Regarding Fire Incident at Asa Plant (Kawahigashi) PDF
2025/11/12
Nippon Kayaku announces New Product Launch: IBTROZIⓇCapsules 200mg
2025/09/25
Annual update has been made to our Sustainability site.
2025/09/19
Nippon Kayaku announces IBTROZIⓇCapsules 200mg (taletrectinib) has been approved in Japan for patients with unresectable advanced and/or recurrent ROS1-positive non-small cell lung cancer
2025/08/25
Announcement of Joint Venture Establishment and Shareholders Agreement Execution
2025/07/09
Nippon Kayaku Selected as a Constituent of all ESG Indices by GPIF
2025/06/12
Nippon Kayaku announces IBTROZITM approved in the U.S. for patients with advanced ROS1-positive Non-Small Cell Lung Cancer
2025/06/02
Presentation of new data from pivotal phase II clinical studies of taletrectinib, a novel ROS1 inhibitor, in patients with advanced ROS1-positive Non-Small Lung Cancer at ASCO 2025
2025/05/30
Topline Results of Phase III BURAN Trial Evaluating Buparlisib (AN2025) in Combination with Paclitaxel for Recurrent or Metastatic HNSCC
2025/05/08
Nippon Kayaku received MSCI ESG Ratings of AA for the second year
2025/03/03
Nippon Kayaku announces completion of marketing authorization application of a novel ROS1 inhibitor, taletrectinib, for use in patients with advanced ROS1-positive Non-Small Cell Lung Cancer in Japan
2025/01/07
Nippon Kayaku Selected as constituent of FTSE4Good Index Series, FTSE Blossom Japan Index, and FTSE Blossom Japan Sector Relative Index
2024/11/01
Presentation of a global phase II clinical study of a novel ROS1 inhibitor, taletrectinib, in patients with advanced ROS1-positive Non-Small Cell Lung Cancer.
2024/10/10
Annual update has been made to our Sustainability site.
2024/05/08
Received ‘AA’ for the first time in MSCI ESG Ratings
2023/12/15
NIPPON KAYAKU ANNOUNCES EXCLUSIVE LICENSING AND COMMERCIALISATION AGREEMENT WITH BIOCHEETAH FOR VECanDx TM IN JAPAN
2023/10/19
Updated information of sustainability
2023/10/18
Trastuzumab BS for I.V. Infusion 60mg “NK”・150mg “NK” Obtained Approval for Additional Indication
2023/09/25
Nippon Kayaku and Celltrion Announce Marketing Approval in Japan for Adalimumab Biosimilar Monoclonal Antibody. PDF
PageTop
Our Business
R&D
Corporate Information
Global Netowork
Investor Relations
Integrated report
Sustainability